https://www.selleckchem.com/pr....oducts/ly3023414.htm
Pulmonary arterial hypertension (PAH) is a devastating complication of Systemic Sclerosis (SSc). Screening for PAH in SSc has increased detection, allowed early treatment for PAH, and improved patient outcomes. Blood-based biomarkers that reliably identify SSc patients at risk of PAH, or with early disease, would significantly improve screening, potentially leading to improved survival, and provide novel mechanistic insights into early disease. The main objective of this study was to identify a proteomic biomarker signature that could
Beğen
Yorum Yap
Paylaş
